InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,238.80
(
1.54%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.16
(
0.01%
)
Bitcoin
63,967.48
(
-0.80%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

joecarry

Send PM Follow Ignore
Followers 0
Posts 94
Boards Moderated 0
Alias Born 07/02/2015

joecarry

Re: pbear post# 92890

Monday, 02/22/2016 7:40:17 PM

Monday, February 22, 2016 7:40:17 PM

Post# of 92948
Ocata’s chief scientific officer to stay with Astellas following acquisition:

Robert Lanza, one of the most prominent scientists in the field of stem cell biology, Monday said he will lead global regenerative medicine research for Astellas Pharma Inc., the Japanese drug maker that acquired his Massachusetts-based company earlier this month.

Lanza said in an interview that he will also remain in his current role of chief scientific officer at Astellas-owned Ocata Therapeutics Inc. in Marlborough, which is developing stem cell therapies for a broad range of diseases.

https://www.bostonglobe.com/business/2016/02/22/ocata-chief-scientific-officer-join-astellas-head-global-regenerative-medicine/pptDFkpb3d6ei0b8x5PlKN/story.html


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up